Elevate Medical Affairs Podcast Channel

Teams are traditionally smaller in MedTech than in Pharma. In MedTech companies, the MA professional may be asked to manage smaller teams and broader areas of responsibilities. This may be the case if you work for a smaller Pharma company, but larger Pharma companies may require more focused responsibilities. 

Hosts John Pracyk, MD, PhD, MBA, Worldwide Integrated Leader, Medical Affairs, Pre-Clinical & Clinical Research, Depuy Synthes - Spine | Johnson & Johnson Medical Devices Companies and Marc Rubinstein, MD, Medical Director at Instrumentation Laboratory, welcome panelists Huub Kreuwel PhD, Vice President of Scientific and Medical Affairs at Octapharma, and Sean Lilienfeld MBBCh, MMEd(Neuro), FCP (Neuro), FAAN, a neurologist by training, and currently Vice President of Global Medical Affairs Clinical Operations, Pre-Clinical Research, and Clinical Strategy at Boston Scientific, two professionals who have successfully transitioned careers between MedTech and Pharma, and reciprocally, Pharma and MedTech.

Do you possess the ability to empathize, but also the business acumen to understand your audience? MA professionals interact with a variety of stakeholders, so you must possess the skills necessary to be relatable and to present information in a meaningful way to a wide audience. 

Ralph Rewers, PharmD, AbbVie’s Global Head, Field Medical Excellence pulled together a group of experts who will discuss the differences in the types of Field Medical that they’re looking to hire. This panel at the Field Medical session on March 8 in Miami includes Nancy Ortiz, PharmD, Executive Director, GMA & Field Medical at Stonebridge Biopharma, Steve McLaughlin, Regional Director, US Rare Disease Field Based MSLs, Sanofi Genzyme and Brooke M. Kim, RN, BSN, MSM who serves as the AbbVie National Director, Oncology Field Medical. The podcast will highlight topics to be discussed, such as rotational assignments, career ladders, and internal and external engagements 

Change is the only constant in the MSL role. Panelists at the session of the March 8 Field Medical Program in Miami will prepare attendees by discussing influences on the MSL role, the rationale for emerging Field Medical roles, and key skill sets to ensure success. Speaking will be: John Pracyk, MD, PhD, MBA, DePuy Synthes – Spine, Johnson & Johnson Medical Devices Companies, Worldwide Integrated Leader, Medical Affairs, Pre-Clinical & Clinical Research, Chris Brock, PharmD, Field Based Medical Affairs Head, Respiratory at GlaxoSmithKline, Joseph Medicis, PharmD Executive Director and Head of Medical Affairs at Allena Pharmaceuticals, Michelle Powell, PharmD, Director, Field Medical Excellence, Astellas Pharma Global Development and Kyle Kennedy, VP, Customer Strategy at The Medical Affairs Company.

Host Robin Winter-Sperry MD, Head of Global Field Based Medical Excellence & Insights at Sanofi Genzyme introduces Donna Holder PharmD, Executive Director, Global Field Medical Center of Excellence (CoE) at Merck, and Ralph Rewers PharmD, AbbVie’s Global Head, Field Medical Excellence who organized this specialized course that is being offered at the MAPS annual meeting on March 8 in Miami.

Are you keeping up with the data and science that are driving the profession? The panelists who will be highlighting the critical importance of adult learning principles and certification of knowledge to career training insights on March 8 in Miami are: Donna Holder, PharmD, Executive Director, Global Field Medical Center of Excellence (CoE) at Merck, Stephen Valerio, MS, CMP, AstraZeneca Senior Director of Oncology Medical Training, Urvashi Vashee, PharmD, Team Lead Director, Global Scientific Training Oncology at Merck & Co, and Danielle C. Heuer, Director of WD Communications.

How can global leaders set affiliates up for success? Charlotte Kremer MD MBA, EVP of Medical Affairs for Astellas, and current MAPS President, speaks to the importance of sharing information in real time.

Patients want the best medicine and therapy available. Merinke Kuiper-Lenters, MD, a physician and patient who was diagnosed with autoimmune vasculitis, explains patient expectations from the pharma industry. 

What does the future of MA look like from a commercial perspective? Robert "Bobby" Mulrooney, MD, General Manager, UK & Ireland for Portola Pharmaceuticals, shares his candid opinions as to how MA can be a driver of strategy with commercial partners.